Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Filtronic

    MCap

    GBP107m

    Last close

    GBP0.49

    ▲ 16.00 (48.48%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

ImmuPharma (IMMX)

Last close As at 25/04/2024

USD2.13

▲ −0.17 (−7.39%)

Market capitalisation

USD57m

ImmuPharma is a UK drug development company linked to the leading French research organisation (CNRS). The lead project, Lupuzor, is in a Phase IIb trial with partner Cephalon for lupus. A new peptide cancer product, Nucant-6L, has entered Phase I/II studies.

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (US$m)

15.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (35.3) (54.5) 19.0
Relative (33.2) (56.3) (2.9)
52 week high/low 7.3p/1.6p

Financials

ImmuPharma’s ability to secure a new partner for Lupuzor, having re-claimed the rights in the wake of Teva’s acquisition of Cephalon, is fundamental to its investment case and provides a major near-term catalyst. ImmuPharma believes it can secure a deal on terms at least as good as those with Cephalon – $45m upfront in a $500m plus royalties deal – given the product is now Phase III-ready, has an SPA and fast-track status in place.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (0.5) (0.6) (50.88) N/A N/A
2021A 0.0 (1.4) (1.3) (35.91) N/A N/A
2022E 0.0 (6.2) (5.9) (42.56) N/A N/A
2023E 0.0 (8.8) (8.8) (63.12) N/A N/A

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free